Protecting the gastrointestinal (GI) tract from cancer therapy
Side effects of radiation and chemotherapy include gut epithelial cell death and gut barrier damage, known as GI mucositis. This damage initiates a cycle of inflammation and infection, and may lead to sepsis and death. Patients with GI mucositis may experience symptoms that include inability to swallow, ulcerations of the GI tract, bleeding, diarrhea, stool incontinence, or in severe cases, GI tissue necrosis. Synedgen is developing first-in-class cancer adjunctive therapeutics to repair GI mucositis injury, promote healing, and restore a healthy microbiome. Our lead drug, SYGN305, is being developed to help patients tolerate cancer therapy by managing acute GI side effects and preventing lasting damage to the GI tract.
October 19, 2021
SWM International’s Scapa Healthcare Business Signs Exclusive Technology Licensing Agreement for Novel Wound Care Technology with Synedgen, Inc.
August 5, 2021
Synedgen Initiates Clinical Trial Assessing Combination of SynePure and Catasyn for the Treatment of Partial Thickness Burns
February 18, 2021
Synedgen Appoints Industry Veteran Dennis Fenton, Ph.D., to Board of Directors